https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-05 17:00:052024-09-05 17:00:05Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
https://www.optimumcomms.com/wp-content/uploads/2024/01/Vivet_Logo_300x180px-80x80-1.png
758
1104
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-05 09:13:532024-09-05 09:13:53European Commission Grants Orphan Drug Designation for Vivet Therapeutics Gene Therapy Product for the Treatment of Cerebrotendinous Xanthomatosis (CTX)
https://www.optimumcomms.com/wp-content/uploads/2023/12/Vesper_Bio_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-04 08:32:082024-09-04 08:32:08Vesper Bio announces successful Phase I study for potentially disease-modifying treatment for frontotemporal dementia
https://www.optimumcomms.com/wp-content/uploads/2024/09/QL-Biopharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-03 08:38:142024-09-03 08:44:31QL Biopharm Announces Abstract on Novel Ultra Long-acting GLP-1RA to be Presented at EASD Annual Meeting 2024
https://www.optimumcomms.com/wp-content/uploads/2023/02/AMSilk_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-03 08:37:072024-09-03 08:37:07AMSilk joins World Economic Forum’s Global Innovators Community
https://www.optimumcomms.com/wp-content/uploads/2023/06/adcendo_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-08-20 08:35:432024-08-20 08:35:43Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-08-14 09:10:042024-08-14 09:10:04CEO appointed to lead Denmark’s AI supercomputer initiative
https://www.optimumcomms.com/wp-content/uploads/2023/02/Calliditas_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-08-13 08:50:172024-08-13 08:50:17Calliditas Interim Report January to June 2024
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-08-01 08:41:002024-08-01 08:41:00Novo Holdings Invests in UK-Listed Oxford Nanopore Technologies
https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-26 16:21:042024-07-26 16:21:04Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-26 09:29:402024-07-26 09:29:40Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ariceum_Logo_300x180px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-25 08:39:322024-07-25 08:39:32Ariceum Therapeutics Commences Phase 1 Clinical Trial in Patients with Recurrent Glioblastoma
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-23 12:38:252024-07-23 12:38:57Novo Holdings leads $105 million financing of Magenta Medical to support FDA approval for world’s smallest heart pump
https://www.optimumcomms.com/wp-content/uploads/2024/04/Xeltis_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-23 08:42:522024-07-23 11:27:44Xeltis appoints Shawn Gage as Vice President of US Clinical Affairs
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-18 14:32:502024-07-18 14:32:50Novo Holdings Portfolio Company Invetx to be Acquired by Dechra Pharmaceuticals
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-16 10:23:582024-07-16 10:23:584SC receives Orphan Drug Status (ODS) for resminostat (Kinselby) in cutaneous T-cell lymphoma in Switzerland
https://www.optimumcomms.com/wp-content/uploads/2024/01/Vivet_Logo_300x180px-80x80-1.png
758
1104
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-16 09:37:502024-07-16 09:37:50Dr Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer of Vivet Therapeutics Receives the Rosalind Franklin Society Special Award in Science
https://www.optimumcomms.com/wp-content/uploads/2023/02/ASCEneuron_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-16 08:25:152024-07-16 08:25:15Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-16 08:17:162024-07-16 08:17:16Novo Holdings leads $100 million Series C financing of Asceneuron to advance groundbreaking therapy for Alzheimer’s disease
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-07-11 09:03:192024-07-11 09:03:32Heidelberg Pharma Reports on First Half-Year 2024 and the Course of BusinessFor more information about Optimum Strategic Communications, please get in touch.
